1. Hepatic Proteomic Changes Associated with Liver Injury Caused by Alcohol Consumption in Fpr2−/− Mice
- Author
-
Josiah E. Hardesty, Jeffrey B. Warner, Daniel W. Wilkey, Brett S. Phinney, Michelle R. Salemi, Michael L. Merchant, Craig J. McClain, Dennis R. Warner, and Irina A. Kirpich
- Subjects
alcohol-associated liver disease ,FPR2 ,liver proteome ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Alcohol-associated liver disease (ALD) is a prevalent medical problem with limited effective treatment strategies. Although many biological processes contributing to ALD have been elucidated, a complete understanding of the underlying mechanisms is still lacking. The current study employed a proteomic approach to identify hepatic changes resulting from ethanol (EtOH) consumption and the genetic ablation of the formyl peptide receptor 2 (FPR2), a G-protein coupled receptor known to regulate multiple signaling pathways and biological processes, in a mouse model of ALD. Since previous research from our team demonstrated a notable reduction in hepatic FPR2 protein levels in patients with alcohol-associated hepatitis (AH), the proteomic changes in the livers of Fpr2−/− EtOH mice were compared to those observed in patients with AH in order to identify common hepatic proteomic alterations. Several pathways linked to exacerbated ALD in Fpr2−/− EtOH mice, as well as hepatic protein changes resembling those found in patients suffering from AH, were identified. These alterations included decreased levels of coagulation factors F2 and F9, as well as reduced hepatic levels of glutamate-cysteine ligase catalytic subunit (GCLC) and total glutathione in Fpr2−/− EtOH compared to WT EtOH mice. In conclusion, the data suggest that FPR2 may play a regulatory role in hepatic blood coagulation and the antioxidant system, both in a pre-clinical model of ALD and in human AH, however further experiments are required to validate these findings.
- Published
- 2024
- Full Text
- View/download PDF